Breast Cancer Molecular Subtypes in Patients With Locally Advanced Disease: Impact on Prognosis, Patterns of Recurrence, and Response to Therapy

Seminars in Radiation Oncology

Volumn 19, Issue 4, 2009, Pages 204-210

  Huber, Kathryn E ^a,b   Carey, Lisa A ^c   Wazer, David E ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

BRAIN METASTASIS; BREAST CANCER; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CELL HETEROGENEITY; CLINICAL TRIAL; DISTANT METASTASIS; GENE EXPRESSION PROFILING; HUMAN; LYMPH NODE METASTASIS; MASTECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL TIME; TREATMENT RESPONSE;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, ERBB-2; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 69249203702     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2009.05.004     Document Type: Review

References (55)

1. Fisher E.R., Redmond C.K., Liu H., et al. Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer 45 (1980) 349-353
2. Jemal A., Thun M.J., Ries L.A., et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100 (2008) 1672-1694
3. Jemal A., Ward E., and Thun M.J. Recent trends in breast cancer incidence rates by age and tumor characteristics among US women. Breast Cancer Res 9 (2007) R28
4. Burrell H.C., Sibbering D.M., Wilson A.R., et al. Screening interval breast cancers: Mammographic features and prognosis factors. Radiology 199 (1996) 811-817
5. Groenendijk R.P., Bult P., Tewarie L., et al. Screen-detected breast cancers have a lower mitotic activity index. Br J Cancer 82 (2000) 381-384
6. Porter P.L., El-Bastawissi A.Y., Mandelson M.T., et al. Breast tumor characteristics as predictors of mammographic detection: Comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91 (1999) 2020-2028
7. Dent R., Trudeau M., Pritchard K.I., et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13 (2007) 4429-4434
8. Sihto H., Lundin J., Lehtimaki T., et al. Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res 14 (2008) 4103-4110
9. Chang S., Parker S.L., Pham T., et al. Inflammatory breast carcinoma incidence and survival: The surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer 82 (1998) 2366-2372
10. Guérin M., Gabillot M., Mathieu M.C., et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: Prognostic significance. Int J Cancer 43 (1989) 201-208
11. Kleer C.G., Zhang Y., Pan Q., et al. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res 6 (2004) R110-R115
12. Bertucci F., Finetti P., Rougemont J., et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 65 (2005) 2170-2178
13. Van Laere S.J., Van den Eynden G.G., Van der Auwera I., et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat 95 (2006) 243-255
14. Greene F., Page D., and Fleming I. AJCC cancer staging manual (2002), Springer-Verlag, New York, NY
15. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
16. Fisher B., Redmond C., Brown A., et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1 (1983) 227-241
17. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 235 (1987) 177-182
18. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
19. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
20. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
21. Sørlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98 (2001) 10869-10874
22. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression datasets. Proc Natl Acad Sci U S A 100 (2003) 8418-8423
23. Sotiriou C., Neo S.Y., McShane L.M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100 (2003) 10393-10398
24. Fan C., Oh D.S., Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355 (2006) 560-569
25. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. J Am Med Assoc 295 (2006) 2492-2502
26. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (2004) 5367-5374
27. Sørlie T. Molecular portraits of breast cancer: Tumor subtypes as distinct disease entities. Eur J Cancer 40 (2004) 2667-2675
28. Parker J., Mullins M., Cheang M.C.U., et al. A supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27 (2009) 1160-1167
29. Bauer K.R., Brown M., Cress R.D., et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer registry. Cancer 109 (2007) 1721-1728
30. Millikan R.C., Newman B., Tse C.K., et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109 (2008) 123-139
31. Crabb S.J., Cheang M.C., Leung S., et al. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer 8 (2008) 249-256
32. Foulkes W.D., Grainge M.J., Rakha E.A., et al. Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat (2008) July 4, [Epub ahead of print]
33. Halperin E.C., Perez C.A., and Brady L.W. Perez and Brady's Principles and Practice of Radiation Oncology (2007), Wolters Kluwer, Conshohocken, PA
34. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 (2005) 5678-5685
35. Rody A., Karn T., Solbach C., et al. The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast 16 (2007) 235-240
36. Carey L.A., Dees E.C., Sawyer L., et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13 (2007) 2329-2334
37. Goldstein N.S., Decker D., Severson D., et al. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 110 (2007) 1687-1696
38. Guarneri V., Broglio K., Kau S.W., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24 (2006) 1037-1044
39. Fernández-Morales L.A., Seguí M.A., Andreu X., et al. Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status. Clin Breast Cancer 7 (2007) 559-564
40. Sânchez-Muñoz A., García-Tapiador A.M., Martínez-Ortega E., et al. Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Trans Oncol 10 (2008) 646-653
41. Colleoni M., Viale G., Zahrieh D., et al. Expression of ER, PGR, HER1, HER2, and response: A study of preoperative chemotherapy. Ann Oncol 19 (2008) 465-472
42. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 (1998) 2672-2685
43. Kuerer H.M., Newman L.A., Smith T.L., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17 (1999) 460-469
44. Liedtke C., Mazouni C., Hess K.R., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26 (2008) 1275-1281
45. Gianni L., Zambetti M., Clark K., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23 (2005) 7265-7277
46. Kyndi M., Sørensen F.B., Knudsen H., et al. Estrogen receptor, progesterone receptor, Her-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol 26 (2008) 1419-1426
47. Nguyen P.L., Taghian A.G., Katz M.S., et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and Her-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26 (2008) 2373-2378
48. Haffty B.G., Yang Q., Reiss M., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24 (2006) 5652-5657
49. Dent R., Hanna W.M., Trudeau M., et al. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115 (2009) 423-428
50. Lin N.U., Claus E., Sohl J., et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases. Cancer 113 (2008) 2638-2645
51. Smid M., Wang Y., Zhang Y., et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 68 (2008) 3108-3114
52. Gabos Z., Sinha R., Hanson J., et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24 (2006) 5658-5663
53. Liang K., Lu Y., Jin W., et al. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2 (2003) 1113-1120
54. Pietras R.J., Poen J.C., Gallardo D., et al. Monoclonal antibody to Her-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59 (1999) 1347-1355
55. Buchholz T.A., Huang E.H., Berry D., et al. HER2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 1337-1342